**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event\* Drug interaction

A 61-year-old man developed leucopenia, pancreatitis and BK polyomavirus during treatment with mycophenolate, and influenza-A infection and coronavirus disease 2019 (COVID-19) pneumonia during treatment with prednisone and tacrolimus. The concomitant administration of lopinavir/ritonavir and tacrolimus decreased the clearance of tacrolimus. He also received off-label therapy lopinavir/ritonavir, nitazoxanide and immune-globulin for COVID-19 pneumonia. \[*durations of treatments to reactions onsets not stated; not all routes and dosages and outcomes stated*\].

The man had a significant history of coronary artery disease, hypertension, end-stage renal disease (on haemodialysis from 2014), and end-stage heart failure due to arrhythmogenic right ventricular cardiomyopathy. In May 2019, he underwent dual organ heart-kidney transplantation. Initially, he received immunosuppressive therapy with mycophenolate. However, 2 months following transplantation, treatment with mycophenolate was discontinued due to leucopenia, pancreatitis and detectable BK polyomavirus.

The man received immunosuppressive therapy with tacrolimus (at target level of 8 ng/mL) and low-dose prednisone 5 mg/day. Eight months following transplantation, he developed mild influenza-A infection. Hence, he received oseltamivir for 10 days. Six weeks later (10 months after transplantation), he presented with yellow sputum productive cough for 3 days, pleuritic chest pain, nasal congestion, dyspnoea and subjective fevers. He denied travelling or exposure to known individuals with COVID-19 infection. His vital signs were normal, physical examination was unremarkable and oxygen saturation was 96% (on room air). Additionally, WBC count and blood lactate were normal along with negative respiratory viral panel. Laboratory investigations showed a decreased absolute lymphocyte count and increased CRP. His initial chest X-ray demonstrated multifocal pneumonia. Hence, empiric therapy with piperacillin/tazobactam, azithromycin and vancomycin. His treatment with prednisone was discontinued and the dose of tacrolimus was decreased to a target level of 6−8 ng/mL. He also received prophylaxis therapy with atovaquone and ganciclovir. Thereafter, nasopharyngeal and oropharyngeal swabs were sent for COVID-19 testing. He was hospitalised and kept in an airborne isolation bed. On day 4 of hospitalisation, he was clinically stable and oxygen saturation was 95% (on room air). However, chest X-ray showed bilateral worsening airspace opacities and pleural effusions and COVID-19 testing was positive. Therefore, treatment with lopinavir/ritonavir 400/100mg every 12 hours and nitazoxanide 500mg every 12 hours were initiated for 7 days. He also received a single dose of IV immune-globulin 40g \[immunoglobulin\]. Due to a known drug-drug interaction between ritonavir and tacrolimus, the levels of tacrolimus were monitored daily. Thereafter, a decreased tacrolimus clearance was noted secondary to drug-drug interaction, and he did not require tacrolimus for a week. Anti-bacterial therapy was discontinued and his condition improved by day 14 of hospitalisation. His had intermittent cough with scant sputum production and CRP level was decreased. Hence, he was discharged home for further self-care.
